Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

St Louis, Missouri

CNS medication trials in St Louis, MO

38 CNS medication studies are recruiting participants at sites in St Louis as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

St Louis at a glance

Depression studies recruiting in St Louis

Basic details from each study's public record (the 30 most recently updated of 38). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Psilocybin-Assisted Therapy as a Treatment for Depression

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Washington University School of Medicine
    Study site
    Washington University School of Medicine
    Registry record
    NCT07582120 · updated
  2. A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Seaport Therapeutics
    Study site
    Seaport Investigator Site
    Registry record
    NCT07065240 · updated
  3. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Definium Therapeutics US, Inc.
    Study site
    Arch Clinical Trials, LLC
    Registry record
    NCT07592689 · updated
  4. A Study of Brenipatide in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Arch Clinical Trials
    Registry record
    NCT07412756 · updated
  5. Study of ALTO-300 in MDD

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT05922878 · updated
  6. ALTO-207 in Adults With Treatment-resistant Depression (TRD)

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT07553637 · updated
  7. Lumateperone for Late-Life Depression

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    Eric Lenze
    Study site
    Washington University School of Medicine
    Registry record
    NCT07623135 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in St Louis, MO on ClinicalTrials.gov.

Schizophrenia studies recruiting in St Louis

  1. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    Tekton Research, LLC - Saint Louis Psychiatry - PPDS
    Registry record
    NCT06585787 · updated
  2. A Study of Brenipatide in Adult Participants With Schizophrenia

    • Phase 2
    • Ages 18 to 55
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Arch Clinical Trials
    Registry record
    NCT07410507 · updated
  3. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT07114874 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in St Louis, MO on ClinicalTrials.gov.

Bipolar disorder studies recruiting in St Louis

  1. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Arch Clinical Trials
    Registry record
    NCT06951711 · updated
  2. A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Arch Clinical Trials
    Registry record
    NCT07140913 · updated
  3. A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Arch Clinical Trials
    Registry record
    NCT06929273 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in St Louis, MO on ClinicalTrials.gov.

Parkinson's disease studies recruiting in St Louis

  1. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Washington University - School of Medicine ( Site 5006)
    Registry record
    NCT06952504 · updated
  2. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Washington University Siteman Cancer Center ( Site 0031)
    Registry record
    NCT06966700 · updated
  3. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    AstraZeneca
    Registry record
    NCT06989112 · updated
  4. An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

    • Phase 2
    • Ages 50 to 80
    • All sexes
    Sponsor
    Yale University
    Study site
    Washington University
    Registry record
    NCT06996652 · updated
  5. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Washington Uni School of Medicine
    Registry record
    NCT07174310 · updated
  6. A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Washington University School of Medicine ( Site 0076)
    Registry record
    NCT06312176 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in St Louis, MO on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in St Louis

  1. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Siteman Cancer Center at Christian Hospital · Siteman Cancer Center-South County · Washington University School of Medicine
    Registry record
    NCT03816345 · updated
  2. A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 60
    • All sexes
    Sponsor
    Zenas BioPharma (USA), LLC
    Study site
    Washington University School of Medicine
    Registry record
    NCT07299019 · updated
  3. A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 60
    • All sexes
    Sponsor
    Zenas BioPharma (USA), LLC
    Study site
    Washington University School of Medicine
    Registry record
    NCT07067463 · updated
  4. A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Celgene
    Study site
    Washington University School of Medicine
    Registry record
    NCT06782490 · updated
  5. Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

    • Phase 3
    • Ages 40 to 70
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    WA Uni School Of Med
    Registry record
    NCT06846281 · updated
  6. Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT05877963 · updated
  7. Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

    • Phase 1/2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Tr1X, Inc.
    Study site
    Washington University, St. Louis
    Registry record
    NCT07477639 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in St Louis, MO on ClinicalTrials.gov.

Epilepsy studies recruiting in St Louis

  1. A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    Saint Louis University Medical School
    Registry record
    NCT05667142 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in St Louis, MO on ClinicalTrials.gov.

Migraine studies recruiting in St Louis

  1. Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

    • Phase 4
    • Ages 18 to 70
    • All sexes
    Sponsor
    Mayo Clinic
    Study site
    Washington University St Louis
    Registry record
    NCT06972056 · updated
  2. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Sundance Clinical Research
    Registry record
    NCT07645924 · updated
  3. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Sundance Clinical Research
    Registry record
    NCT07674654 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in St Louis, MO on ClinicalTrials.gov.

Ask about studies near St Louis

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call